GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant ...

Researchers compared a traditional Chinese medicine, Yueju Pill, with a standard antidepressant and found both reduced ...

After administering more than 23,000 ketamine treatments over the past 5 years, we obviously believe in the drug’s importance—saving and changing lives of many patients who suffer from intractable ...

Almost half of patients diagnosed with depression classify as being ‘treatment-resistant’ as new research suggests that many don’t respond to multiple antidepressant options. The new study, published ...

A small company can now advance its psychedelic into phase 3. Here’s why that matters to other psychedelic biotechs. A small ...

Treatment-resistant (refractory) depression has been a fertile topic for several decades (e.g., Freyhan, 1978; Nierenberg & Amsterdam, 1990; Voineskos, 2020). Unfortunately, as noted by Voineskos, ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, and long-term safety data to reduce costly treatment-resistant depression.

The FDA lifted its clinical hold on GH Research's GH001 after Phase 2b data showed rapid, durable benefits in ...

Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer ...